KR20160067195A - 피부 질환 치료에서의 국소적 사용을 위한 니코틴아미드 리보사이드 조성물 - Google Patents

피부 질환 치료에서의 국소적 사용을 위한 니코틴아미드 리보사이드 조성물 Download PDF

Info

Publication number
KR20160067195A
KR20160067195A KR1020167014302A KR20167014302A KR20160067195A KR 20160067195 A KR20160067195 A KR 20160067195A KR 1020167014302 A KR1020167014302 A KR 1020167014302A KR 20167014302 A KR20167014302 A KR 20167014302A KR 20160067195 A KR20160067195 A KR 20160067195A
Authority
KR
South Korea
Prior art keywords
salt
nicotinamide riboside
skin
sodium
chloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020167014302A
Other languages
English (en)
Korean (ko)
Inventor
앤 데렌-르위스
트로이 로네무스
Original Assignee
크로마덱스 아이엔씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 크로마덱스 아이엔씨. filed Critical 크로마덱스 아이엔씨.
Priority to KR1020217026414A priority Critical patent/KR20210107895A/ko
Publication of KR20160067195A publication Critical patent/KR20160067195A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/048—Pyridine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Birds (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
KR1020167014302A 2013-10-30 2014-10-30 피부 질환 치료에서의 국소적 사용을 위한 니코틴아미드 리보사이드 조성물 Ceased KR20160067195A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020217026414A KR20210107895A (ko) 2013-10-30 2014-10-30 피부 질환 치료에서의 국소적 사용을 위한 니코틴아미드 리보사이드 조성물

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361897713P 2013-10-30 2013-10-30
US61/897,713 2013-10-30
PCT/US2014/063260 WO2015066382A1 (en) 2013-10-30 2014-10-30 Nicotinamide riboside compositions for topical use in treating skin conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020217026414A Division KR20210107895A (ko) 2013-10-30 2014-10-30 피부 질환 치료에서의 국소적 사용을 위한 니코틴아미드 리보사이드 조성물

Publications (1)

Publication Number Publication Date
KR20160067195A true KR20160067195A (ko) 2016-06-13

Family

ID=53005146

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020217026414A Ceased KR20210107895A (ko) 2013-10-30 2014-10-30 피부 질환 치료에서의 국소적 사용을 위한 니코틴아미드 리보사이드 조성물
KR1020167014302A Ceased KR20160067195A (ko) 2013-10-30 2014-10-30 피부 질환 치료에서의 국소적 사용을 위한 니코틴아미드 리보사이드 조성물
KR1020227022241A Ceased KR20220098049A (ko) 2013-10-30 2014-10-30 피부 질환 치료에서의 국소적 사용을 위한 니코틴아미드 리보사이드 조성물

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020217026414A Ceased KR20210107895A (ko) 2013-10-30 2014-10-30 피부 질환 치료에서의 국소적 사용을 위한 니코틴아미드 리보사이드 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020227022241A Ceased KR20220098049A (ko) 2013-10-30 2014-10-30 피부 질환 치료에서의 국소적 사용을 위한 니코틴아미드 리보사이드 조성물

Country Status (12)

Country Link
US (2) US10688118B2 (enExample)
EP (1) EP3063163B1 (enExample)
JP (1) JP6509844B2 (enExample)
KR (3) KR20210107895A (enExample)
CN (2) CN109985056A (enExample)
AU (1) AU2014342185B2 (enExample)
CA (1) CA2928656C (enExample)
ES (1) ES2925879T3 (enExample)
MX (2) MX394291B (enExample)
NZ (1) NZ719328A (enExample)
WO (1) WO2015066382A1 (enExample)
ZA (1) ZA201603314B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020122547A1 (ko) * 2018-12-14 2020-06-18 주식회사 휴메딕스 지방알코올 컨쥬게이션된 니코틴아미드 리보사이드 유도체
KR20210077156A (ko) 2019-12-17 2021-06-25 주식회사 휴메딕스 지방아민 컨쥬게이션된 니코틴아미드 리보사이드 유도체
KR20240000152A (ko) * 2022-06-23 2024-01-02 제너럴바이오(주) Nr, nmn 및 nad를 함유한 피부 주름 개선용 화장료 조성물

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016015997A (es) * 2014-06-02 2017-04-05 Glaxosmithkline Intellectual Property (No 2) Ltd Preparacion y uso de beta-d-nicotinamida ribosido cristalina.
US10485814B2 (en) 2014-06-06 2019-11-26 Glaxosmithkline Intellectual Property (No. 2) Limited Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof
CA2956163C (en) 2014-07-24 2023-01-10 W.R. Grace & Co.-Conn. Crystalline form of nicotinamide riboside
CN107428791B (zh) 2015-03-09 2024-05-28 格雷斯公司 烟酰胺核苷的结晶形式
KR102426320B1 (ko) 2015-03-16 2022-07-29 크로마덱스 아이엔씨. 니코틴산 리보사이드 또는 니코틴아미드 리보사이드 조성물, 이의 환원 유도체, 및 이의 용도
US20160317420A1 (en) 2015-05-01 2016-11-03 The Procter & Gamble Company Method of improving the appearance of skin and compositions therefor
WO2016178949A1 (en) * 2015-05-01 2016-11-10 The Procter & Gamble Company Method of improving skin health and compositions therefor
EP3288529A1 (en) 2015-05-01 2018-03-07 The Procter and Gamble Company Method of improving the appearance of skin and compositions therefor using nicotinamide riboside
CA2989115C (en) * 2015-06-10 2024-01-02 Elysium Health, Inc. Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders
WO2016210232A1 (en) * 2015-06-25 2016-12-29 N.V. Perricone Llc Niacinamide mononucleotide formulations for skin aging
US20160374918A1 (en) * 2015-06-29 2016-12-29 The Procter & Gamble Company Encapsulated skin care agent
US20160374908A1 (en) 2015-06-29 2016-12-29 The Procter & Gamble Company Skin care composition and methods of using the same
US11013678B2 (en) 2015-06-29 2021-05-25 The Procter & Gamble Company Multi-component skin care product
US9833398B2 (en) 2016-01-11 2017-12-05 The Procter & Gamble Company Method of treating a skin condition and compositions therefor
CA3017254C (en) 2016-03-16 2023-08-22 ChromaDex Inc. B-vitamin and amino acid conjugates of nicotinoyl ribosides and reduced nicotinoyl ribosides, derivatives thereof, and methods of preparation thereof
US10183036B2 (en) 2016-04-20 2019-01-22 ChromaDex Inc. Use of nicotinic acid riboside or nicotinamide riboside derivatives, and reduced derivatives thereof, as NAD+ increasing precursors
WO2018039207A1 (en) 2016-08-22 2018-03-01 Elysium Health, Inc. Nicotinamide riboside and pterostilbene compositions and methods for treatment of neurodegenerative disorders
CN120383644A (zh) 2016-11-11 2025-07-29 英国贝尔法斯特女王大学 烟酰基核苷和还原的烟酰基核苷、其改性衍生物、磷酸化的类似物、腺苷二核苷酸共轭物、以及新颖结晶形式的有效且可规模化的合成
AU2017367092B2 (en) 2016-11-29 2022-11-03 University Of Iowa Research Foundation Use of NAD precursors for improving maternal health and/or offspring health
US11071747B2 (en) 2016-11-29 2021-07-27 University Of Iowa Research Foundation Use of NAD precursors for breast enhancement
CA3047495A1 (en) 2016-12-21 2018-06-28 Unilever Plc Topical skin lightening additive and composition with amino acids and nicotinamide compounds
US11337908B2 (en) 2016-12-21 2022-05-24 Conopco, Inc. Personal care compositions with cystine
US11260005B2 (en) 2016-12-21 2022-03-01 Conopco, Inc. Personal care compositions with glutathione precursor comprising 4-substituted resorcinols and amino acids
WO2018114745A1 (en) 2016-12-21 2018-06-28 Unilever Plc Personal care compositions comprising poorly soluble compounds
RU2651047C1 (ru) * 2017-05-04 2018-04-18 Общество С Ограниченной Ответственностью "Научно-Технологическая Фармацевтическая Фирма "Полисан" Лекарственная композиция цитопротекторного действия и способ ее получения
US20200085849A1 (en) * 2017-05-18 2020-03-19 Elysium Health, Inc. Methods and compositions for improving sleep
EP3642214A2 (en) 2017-06-19 2020-04-29 Gangadhara Ganapati Nicotinamide riboside derivatives and their uses
CN110785161B (zh) 2017-06-23 2023-06-20 宝洁公司 用于改善皮肤外观的组合物和方法
CA3108015A1 (en) 2017-07-28 2019-01-31 Centers For Age Control, Inc. Compositions and methods for preventing and reversing aspects of aging
JP7210459B2 (ja) * 2017-09-14 2023-01-23 めぐみ 田中 老化防止剤及び老化防止方法
GB201716391D0 (en) * 2017-10-06 2017-11-22 Xobaderm Ltd Kit for delivery of an active compound into a biological barrier
CA3086535A1 (en) 2017-12-22 2019-06-27 Elysium Health, Inc. Crystalline forms of nicotinamide riboside chloride
EP3817717A1 (en) 2018-07-03 2021-05-12 The Procter & Gamble Company Method of treating a skin condition
CN110913864B (zh) * 2018-08-17 2022-12-13 邦泰生物工程(深圳)有限公司 一种稳定型烟酰胺核糖组合物及其制备方法
WO2020131578A2 (en) 2018-12-17 2020-06-25 Mitopower Llc Nicotinyl riboside compounds and their uses
EP4471043A3 (en) * 2019-07-19 2025-03-05 Biosynth AG Method of making nicotinamide ribofuranoside salts, nicotinamide ribofuranoside salts as such, and uses thereof
CN110638827A (zh) * 2019-10-17 2020-01-03 泓博元生命科技（深圳）有限公司 Nadh及其盐在制备皮肤色素抑制剂中的应用
CN111166760A (zh) * 2019-12-17 2020-05-19 浙江安赛新材料科技有限公司 β-烟酰胺单核苷酸或其前体的组合物及制备方法、应用
CN111184732B (zh) * 2020-03-04 2023-09-08 武汉华纳联合药业有限公司 一种复合组合物制剂及其制备方法和皮肤炎症中的应用
CN111454311B (zh) * 2020-04-03 2021-10-19 深圳市迪克曼科技开发有限公司 烟酰胺核糖的有机酸盐及其组合物与制备方法
FR3110410A1 (fr) * 2020-05-20 2021-11-26 Nuvamid Sa Compositions cosmétiques anti-âge comprenant de la NMN
WO2021234009A1 (fr) * 2020-05-20 2021-11-25 Nuvamid Sa Compositions cosmetiques anti-age comprenant du nmn
US10959933B1 (en) 2020-06-01 2021-03-30 The Procter & Gamble Company Low pH skin care composition and methods of using the same
US11583488B2 (en) 2020-06-01 2023-02-21 The Procter & Gamble Company Method of improving penetration of a vitamin B3 compound into skin
CN111632049A (zh) * 2020-06-09 2020-09-08 西北农林科技大学 一种通过综合矫正细胞活性氧簇代谢紊乱以缓解睾丸衰老损伤的复合配方
WO2022047182A1 (en) * 2020-08-28 2022-03-03 University Of Washington High dose nicotinamide adenine dinucleotide (nad) precursor regimens for reduction of inflammation in human patients with preexisting inflammation
WO2022157173A1 (en) * 2021-01-19 2022-07-28 Biosynth Ag Method of making nicotinamide ribofuranoside salts by salt metathesis, the crystalline form of its tosylate salt and the co-crystallized form of its chloride:iodide salt
EP4333807A1 (en) * 2021-05-04 2024-03-13 Sovida Solutions Ltd. Nicotinamide adenine dinucleotide (nad) compositions, methods of manufacturing thereof, and methods of use thereof
CN114129509B (zh) * 2021-12-03 2023-12-01 药酚享科技(北京)有限公司 一种保湿性nmn亲水凝胶剂及其制备方法
CN116621898A (zh) * 2022-04-13 2023-08-22 深圳市迪克曼科技开发有限公司 烟酰胺核糖的有机酸盐及其结晶形态、制备方法与用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100369602C (zh) * 2001-02-22 2008-02-20 荷兰联合利华有限公司 改进的皮肤用组合物
US7977049B2 (en) 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
CA2555675A1 (en) 2004-02-10 2005-08-25 Trustees Of Dartmouth College Nicotinamide riboside kinase compositions and methods for using the same
ES2663226T3 (es) 2004-06-04 2018-04-11 Washington University Procedimientos y composiciones para tratar neuropatías
CA2610854A1 (en) 2005-03-30 2006-10-05 Sirtris Pharmaceuticals, Inc. Nicotinamide riboside and analogues thereof
WO2006138418A2 (en) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
CN101257897A (zh) * 2005-07-07 2008-09-03 西特里斯药业公司 用于治疗或预防肥胖、胰岛素抵抗障碍和线粒体相关障碍的方法和相关组合物
JP2009500357A (ja) * 2005-07-07 2009-01-08 サートリス ファーマシューティカルズ， インコーポレイテッド 肥満、インスリン抵抗性障害およびミトコンドリア関連障害を処置または予防するための方法および関連する組成物
ES2670927T3 (es) 2005-11-18 2018-06-04 Cornell Research Foundation, Inc. Composiciones de nicotinoil ribósido y métodos de uso
WO2008110268A1 (en) * 2007-03-12 2008-09-18 Dsm Ip Assets B.V. Cosmetic compositions
US20090069444A1 (en) 2007-09-07 2009-03-12 The United States Of America, As Represented By Th E Secretary Of Agriculture Method to Ameliorate Oxidative Stress and Improve Working Memory Via Pterostilbene Administration
US20130004463A1 (en) * 2010-01-06 2013-01-03 Kabushiki Kaisha Yakult Honsha Dna damage repair promoter for oral application, and elastase activity inhibitor for oral application

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020122547A1 (ko) * 2018-12-14 2020-06-18 주식회사 휴메딕스 지방알코올 컨쥬게이션된 니코틴아미드 리보사이드 유도체
KR20210077156A (ko) 2019-12-17 2021-06-25 주식회사 휴메딕스 지방아민 컨쥬게이션된 니코틴아미드 리보사이드 유도체
KR20240000152A (ko) * 2022-06-23 2024-01-02 제너럴바이오(주) Nr, nmn 및 nad를 함유한 피부 주름 개선용 화장료 조성물

Also Published As

Publication number Publication date
JP6509844B2 (ja) 2019-05-08
ES2925879T3 (es) 2022-10-20
MX394291B (es) 2025-03-24
EP3063163A1 (en) 2016-09-07
KR20210107895A (ko) 2021-09-01
MX2016005574A (es) 2016-12-09
CN105873937A (zh) 2016-08-17
CA2928656A1 (en) 2015-05-07
JP2016538271A (ja) 2016-12-08
WO2015066382A1 (en) 2015-05-07
AU2014342185B2 (en) 2019-01-03
US10688118B2 (en) 2020-06-23
KR20220098049A (ko) 2022-07-08
ZA201603314B (en) 2017-09-27
CA2928656C (en) 2020-07-28
US11033568B2 (en) 2021-06-15
US20200289536A1 (en) 2020-09-17
MX2021009652A (es) 2022-07-26
MX385305B (es) 2025-03-18
EP3063163A4 (en) 2017-05-10
NZ719328A (en) 2022-04-29
CN109985056A (zh) 2019-07-09
EP3063163B1 (en) 2022-08-10
US20160250241A1 (en) 2016-09-01

Similar Documents

Publication Publication Date Title
US11033568B2 (en) Nicotinamide riboside compositions for topical use in treating skin conditions
AU2014342185A1 (en) Nicotinamide riboside compositions for topical use in treating skin conditions
EP3288531B1 (en) Method of improving skin health and compositions therefor
BR9712648B1 (pt) composição compreendendo pelo menos dois compostos selecionados dentre anti-radical, antinflamatório e antialérgico.
US20100286271A1 (en) Nitro-alkyl Compound Compositions
US8816065B2 (en) Pharmaceutical or cosmetic composition containing nicotinic acid adenine dinucleotide phosphate or derivative thereof
US20250127700A1 (en) Methods of treating hyperpigmentation disorders
US20150202187A1 (en) Compositions and methods for treatment of vitiligo
ES2827253T3 (es) Preparación cutánea externa antienvejecimiento
Legiawati Centella asiatica: alternative dry skin therapy in type 2 diabetes mellitus
HK40011054A (en) Nicotinamide nucleoside composition for topical use in the treatment of dermatosis
BR112018011580B1 (pt) Compostos de éster, compostos de amida, composição e uso de pelo menos um composto
JP2007153863A (ja) 毛髪改善外用剤
RU2793250C2 (ru) Композиция и способы лечения патологических состояний кожи; использование света и гидрохлорида глюкозамина
WO2023058731A1 (ja) 皮膚外用組成物及びその利用、並びに皮膚外用組成物原料
MX2007006059A (es) Composicion de crema desmanchadora de piel.

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20160527

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20191018

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20201127

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20210720

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20201127

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20210819

PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20210720

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20210526

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20210923

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20210819

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20210720

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20210526

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20201127

X601 Decision of rejection after re-examination